Thermo Fisher Scientific Inc. (Waltham, Mass.) announced plans to invest more than $600 million in capital investments to expand its bioprocessing production capabilities through 2022. These investments are expected to more than double the company’s current manufacturing capacity and support biopharma customers as they ramp up to meet both the short-term demands related to COVID-19 as well as long-term efforts to develop new vaccines and biologics for other conditions.
“As the bioprocessing market grows, our customers require a consistent and reliable supply of critical materials. Single-use technologies, cell culture media and purification resins are among those in highest demand,” said Michel Lagarde, executive vice president of Thermo Fisher Scientific. “These investments add significant capacity and regional redundancy to further bolster supply chains and help us better support customers as they accelerate the commercialization of lifesaving therapies and vaccines.”
With these investments, the company expects to create more than 1,500 new jobs across 11 manufacturing sites in the Americas, Europe and Asia. Specific investments include:
Single-Use Technologies Expansions
To increase supply chain resiliency across multiple locations on three continents, Thermo Fisher’s single-use technologies business is expanding capacity at sites in Logan, Utah; Millersburg, Pa.; Cramlington, U.K.; Singapore and Suzhou, China. Additional investment at its Santa Clara, Calif. site will expand bioprocessing equipment and automation capacity.
The company will also expand its state-of-the-art POROS resin manufacturing site in Bedford, Mass. and open a new 85,000-square-foot manufacturing facility in Chelmsford, Mass. Together, these sites will reinforce Thermo Fisher’s purification network that specializes in the production of process-scale chromatography resins for a variety of applications, including vaccines and gene therapies.
Cell Culture Media and Process Liquid Expansions
Investments to expand capacity at sites in Grand Island, N.Y.; Miami, Fla. and Inchinnan, Scotland will increase production of Gibco cell culture media, supplements and process liquids as well as the manufacturing of customer-owned proprietary media formulations. These investments provide redundancy to support global supply and further extend capabilities, including harmonizing dual-milling options worldwide.
By Mary Page Bailey
Ideal Cures will operate as a fully independent entity within Colorcon. Their business complements Colorcon’s position in the Indian pharmaceutical market with a strong presence in the domestic generic sector comprised of long-standing customer relationships sustained by innovative and customized solutions.
Across four new breast cancer treatments approved by the FDA last year, 2% to 9% of patients in clinical trials for the drugs were Black Americans and 0% to 9% were Hispanic, according to a new report from Breastcancer.org.
The southern section of Jernbanebyen in central Copenhagen has a new owner. The Baneby Consortium, comprising NREP, Novo Holdings and Industriens Pension, has bought the land from Freja Ejendomme. The ambition is to create a green, partly car-free environment that will also be one of the healthiest in the world.